Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 27;10(2):e0012822.
doi: 10.1128/spectrum.00128-22. Epub 2022 Mar 21.

Comparison of Saliva and Midturbinate Swabs for Detection of SARS-CoV-2

Affiliations

Comparison of Saliva and Midturbinate Swabs for Detection of SARS-CoV-2

Jianyu Lai et al. Microbiol Spectr. .

Abstract

Saliva is an attractive sample for detecting SARS-CoV-2. However, contradictory reports exist concerning the sensitivity of saliva versus nasal swabs. We followed close contacts of COVID-19 cases for up to 14 days from the last exposure and collected self-reported symptoms, midturbinate swabs (MTS), and saliva every 2 or 3 days. Ct values, viral load, and frequency of viral detection by MTS and saliva were compared. Fifty-eight contacts provided 200 saliva-MTS pairs, and 14 contacts (13 with symptoms) had one or more positive samples. Saliva and MTS had similar rates of viral detection (P = 0.78) and substantial agreement (κ = 0.83). However, sensitivity varied significantly with time since symptom onset. Early on (days -3 to 2), saliva had 12 times (95% CI: 1.2, 130) greater likelihood of viral detection and 3.2 times (95% CI: 2.8, 3.8) higher RNA copy numbers compared to MTS. After day 2 of symptoms, there was a nonsignificant trend toward greater sensitivity using MTS. Saliva and MTS demonstrated high agreement making saliva a suitable alternative to MTS for SARS-CoV-2 detection. Saliva was more sensitive early in the infection when the transmission was most likely to occur, suggesting that it may be a superior and cost-effective screening tool for COVID-19. IMPORTANCE The findings of this manuscript are increasingly important with new variants that appear to have shorter incubation periods emerging, which may be more prone to detection in saliva before detection in nasal swabs. Therefore, there is an urgent need to provide the science to support the use of a detection method that is highly sensitive and widely acceptable to the public to improve screening rates and early detection. The manuscript presents the first evidence that saliva-based RT-PCR is more sensitive than MTS-based RT-PCR in detecting SARS-CoV-2 during the presymptomatic period - the critical period for unwitting onward transmission. Considering other advantages of saliva samples, including the lower cost, greater acceptability within the general population, and less risk to health care workers, our findings further supported the use of saliva to identify presymptomatic infection and prevent transmission of the virus.

Keywords: COVID-19; SARS-CoV-2; midturbinate swab; polymerase chain reaction; saliva.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIG 1
FIG 1
Association between Ct values of saliva and MTS samples. Data were from 58 participants and 400 samples. (A) Scatterplot of Ct values of saliva and MTS. (B) Bland-Altman plot for comparison of saliva and MTS.
FIG 2
FIG 2
The change of Ct values and probability of testing positive by days since symptom onset. Data were for MTS and saliva samples from 13 participants who provided a total of 40 pairs of samples and had one or more samples positive for SARS-CoV-2 RNA. (A) Change of Ct values by days since symptom onset. (B) Change of viral RNA copy numbers (natural log scale) by days since symptom onset. (C) Probability of being tested positive by days since symptom onset estimated from a generalized additive logistic model.

Similar articles

Cited by

References

    1. Centers for Disease Control and Prevention. 2021. Interim guidelines for collecting and handling of clinical specimens for COVID-19 testing. Centers for Disease Control and Prevention, Atlanta, Georgia, USA. https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specim....
    1. Congrave-Wilson Z, Lee Y, Jumarang J, Perez S, Bender JM, Bard JD, Pannaraj PS. 2021. Change in saliva RT-PCR sensitivity over the course of SARS-CoV-2 infection. JAMA 326:1065. doi:10.1001/jama.2021.13967. - DOI - PMC - PubMed
    1. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2021. Performance of saliva, oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a systematic review and meta-analysis. J Clin Microbiol 59:e02881-20. doi:10.1128/JCM.02881-20. - DOI - PMC - PubMed
    1. Jamal AJ, Mozafarihashjin M, Coomes E, Anceva-Sami S, Barati S, Crowl G, Faheem A, Farooqi L, Kandel CE, Khan S, Li AX, Mistry H, Paterson A, Plenderleith S, Prost K, Poutanen S, Powis J, Schryer R, Taylor M, Yip L, Zhong XZ, McGeer AJ, Mubareka S, Toronto Invasive Bacterial Diseases Network COVID-19 Investigators . 2021. Sensitivity of midturbinate versus nasopharyngeal swabs for the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Infect Control Hosp Epidemiol 42:1001–1003. doi:10.1017/ice.2020.1326. - DOI - PMC - PubMed
    1. Chu CY, Marais G, Opperman C, Doolabh D, Iranzadeh A, Marais C, Cox H, Williamson C, Hardie D, Brink A. 2021. Performance of saliva and mid-turbinate swabs for detection of the beta variant in South Africa. Lancet Infect Dis 21:1354. doi:10.1016/S1473-3099(21)00405-9. - DOI - PMC - PubMed

Publication types